Prostate cancer is the most common malignancy in men, with more than 200 000 diagnoses and 30 000 deaths per year.
1 Recent advances in technology have led to costlier treatments such as minimally invasive radical prostatectomy, intensity-modulated radiation therapy (IMRT), and proton therapy. The adoption of these technologies resulted in a $350 million increase in health care expenditures in 2005 alone.
2 The Institute of Medicine, Agency for Healthcare Research and Quality, Secretary of the Department of Health and Human Services, and others have called for comparative effectiveness research of localized prostate cancer treatments,
3-5 which is especially relevant for radiation therapy, for which IMRT has gradually replaced the older technique of conformal radiation therapy during the past 10 years. More recently, there has been a substantial increase in the number of proton facilities built, and direct-to-consumer advertising is likely to lead to an increase in its use.
6-8 The clinical benefit from these newer treatments is unproven, and comparative effectiveness research examining different radiation techniques is lacking. Given these trends in use, multiple recent reports have specifically called for research on proton therapy.
9